Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
72.30
Nov 12 • 3:59 PM ET Dollar change-3.09 Percentage change(-4.10%)
Aftermarket Close
72.30
Aftermarket • 7:32 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUI
Market Cap
9.58B
Enterprise Value
9.17B
Income
557.64M
Sales
3.14B
Book/sh
36.15
Cash/sh
3.91
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
6000
IPO
Aug 03, 2012
P/E
17.76
Forward P/E
13.53
PEG
0.98
P/S
3.05
P/B
2.00
P/C
18.51
P/FCF
12.49
EV/EBITDA
9.16
EV/Sales
2.92
Quick Ratio
2.67
Current Ratio
4.30
Debt/Eq
0.02
LT Debt/Eq
0.02
Option/Short
Yes / Yes
EPS (ttm)
4.07
EPS next Y
5.35
EPS next Q
1.29
EPS this Y
25.11%
EPS next Y
7.35%
EPS next 5Y
13.76%
EPS past 3/5Y
28.43% 31.11%
Sales past 3/5Y
42.17% 30.08%
EPS Y/Y TTM
32.22%
Sales Y/Y TTM
13.35%
EPS Q/Q
18.12%
Sales Q/Q
-0.69%
Insider Own
17.55%
Insider Trans
-0.54%
Inst Own
95.26%
Inst Trans
4.78%
ROA
10.50%
ROE
12.13%
ROIC
11.40%
Gross Margin
65.47%
Oper. Margin
22.96%
Profit Margin
17.76%
SMA20
-8.25%
SMA50
-5.70%
SMA200
-12.67%
Trades
Shs Outstand
110.24M
Shs Float
109.23M
52W High
101.40 -28.70%
52W Low
70.39 2.71%
Volatility
4.61% 3.87%
ATR (14)
3.50
RSI (14)
41.87
Beta
0.95
Rel Volume
1.07
Avg Volume
1.58M
Volume
1,694,793
Perf Week
-11.22%
Perf Month
-5.25%
Perf Quarter
-15.83%
Perf Half Y
-6.36%
Perf YTD
-17.19%
Perf Year
-14.65%
Perf 3Y
63.72%
Perf 5Y
-2.02%
Perf 10Y
237.06%
Prev Close
75.39
Price
72.30
Change %
-4.10%
Consensus
Buy
Avg. Price Target
$93.77
Implied Upside
+29.7%
Analysts13incl. previous ratings
Rating Distribution9 Buy · 4 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 06, 2026Downgrade
BMO logoBBMO Capital Markets
Outperform → Market Perform$78+7.9%
Jul 28, 2026Initiated
UBS logoUUBS
Neutral$82+13.4%
Jul 09, 2026Initiated
BMO logoBBMO Capital Markets
Outperform$94+30.0%
Jan 30, 2026Upgrade
NNeedham
Hold → Buy$112+54.9%
Jan 27, 2026Initiated
TD logoTTD Cowen
Buy$110+52.1%
Nov 07, 2025Upgrade
TFC logoTTruist
Hold → Buy$93+28.6%
Nov 07, 2025Upgrade
BAC logoBBofA Securities
Neutral → Buy$91+25.9%
Oct 28, 2025Resumed
SF logoSStifel
Hold$64-11.5%
May 27, 2025Downgrade
BBTIG Research
Buy → Neutral
Jan 10, 2025Upgrade
BAC logoBBofA Securities
Underperform → Neutral$97+34.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TOBIN JAMES RDirectorNov 10 '26Option Exercise56.3041,6662,345,78241,666Nov 12 06:11 PM
TOBIN JAMES RDirectorNov 10 '26Sale75.1641,6663,131,5470Nov 12 06:11 PM
TOBIN JAMES RDirectorNov 10 '26Proposed Sale75.1141,6663,129,392Nov 10 03:11 PM
RHOADS ANN DDirectorNov 04 '26Sale85.005,000425,00035,384Nov 05 05:33 PM
RHOADS ANN DDirectorNov 04 '26Proposed Sale85.005,000425,000Nov 04 02:57 PM
TOBIN JAMES RDirectorSep 15 '26Option Exercise58.7230,0001,761,45030,000Sep 16 04:35 PM
TOBIN JAMES RDirectorSep 15 '26Sale74.5830,0002,237,5020Sep 16 04:35 PM
TOBIN JAMES RDirectorSep 15 '26Proposed Sale74.5330,0002,236,000Sep 15 02:28 PM
ZARRILLI STEPHEN TDirectorAug 18 '26Option Exercise53.2725,0001,331,75025,000Aug 19 05:07 PM
ZARRILLI STEPHEN TDirectorAug 18 '26Sale87.0425,0002,175,9650Aug 19 05:07 PM
ZARRILLI STEPHEN TDirectorAug 18 '26Proposed Sale87.0425,0002,176,000Aug 18 04:23 PM
Davidar David DDirectorJun 05 '26Option Exercise26.2725,000656,750535,175Jun 09 05:04 PM
Davidar David DDirectorJun 05 '26Sale80.7625,0002,019,072510,175Jun 09 05:04 PM
RHOADS ANN DDirectorJun 04 '26Option Exercise26.2725,000656,75040,384Jun 08 05:14 PM
Davidar David DDirectorJun 05 '26Proposed Sale81.0025,0002,025,000Jun 05 03:15 PM
DeFord John AFormer DirectorApr 14 '26Proposed Sale93.1030,0002,793,128Apr 14 03:34 PM
Huller KellyEVP, GC, Corporate SecretaryFeb 25 '26Option Exercise43.5820,000871,60020,000Feb 27 05:53 PM
Huller KellyEVP, GC, Corporate SecretaryFeb 25 '26Sale94.5020,0001,890,0000Feb 27 05:53 PM
Huller KellyOfficerFeb 25 '26Proposed Sale94.4520,0001,889,000Feb 25 03:41 PM
Huller KellyEVP, GC, Corporate SecretaryFeb 12 '26Option Exercise45.6410,000456,40010,000Feb 17 05:22 PM
Huller KellyEVP, GC, Corporate SecretaryFeb 12 '26Sale87.6710,000876,7000Feb 17 05:22 PM
Huller KellyOfficerFeb 12 '26Proposed Sale87.6010,000876,000Feb 12 12:12 PM
Kline KyleSenior Vice President, CFOJan 08 '26Option Exercise51.873,594186,4213,594Jan 12 05:40 PM
Kline KyleSenior Vice President, CFOJan 08 '26Sale101.103,594363,3530Jan 12 05:40 PM
Norwalk Leslie VDirectorJan 08 '26Sale101.102,000202,20010,419Jan 12 05:36 PM
Kline KyleOfficerJan 08 '26Proposed Sale101.053,594363,167Jan 08 01:52 PM
Norwalk Leslie VDirectorJan 08 '26Proposed Sale101.002,000202,000Jan 08 01:10 PM
Norwalk Leslie VDirectorDec 12 '25Sale88.854,000355,40012,419Dec 16 04:18 PM
Norwalk Leslie VDirectorDec 12 '25Proposed Sale88.754,000355,000Dec 12 04:00 PM
Paul David CExecutive ChairmanDec 08 '25Option Exercise25.5234,375877,25060,417Dec 10 04:37 PM
Kline KyleSenior Vice President, CFODec 01 '25Option Exercise59.8618,5421,109,87618,542Dec 03 08:23 PM
Kline KyleSenior Vice President, CFODec 01 '25Sale90.0018,5421,668,7800Dec 03 08:23 PM
Kline KyleOfficerDec 01 '25Proposed Sale89.9518,5421,667,847Dec 01 03:59 PM
Huller KellySVP, GC, Corporate SecretaryNov 25 '25Option Exercise25.967,500194,7007,500Nov 28 05:31 PM
Huller KellySVP, GC, Corporate SecretaryNov 25 '25Sale90.007,500675,0000Nov 28 05:31 PM
Huller KellyOfficerNov 25 '25Proposed Sale90.007,500675,000Nov 25 11:07 AM
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. It engages in developing products that promote healing in patients with musculoskeletal disorders. The firm classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in 2003 and is headquartered in Audubon, PA.
Co-Founder & Executive ChairmanMr. David C. Paul
CEOMr. Keith W. Pfeil
Senior VP & CFOMr. Kyle R. Klin
Executive VPMs. Kelly G. Huller Esq.
Senior Vice President of Business Development & Investor RelationsMr. Brian J. Kearns